Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Gsk Plc ADR (NY: GSK )

34.33 +0.31 (+0.91%)
Official Closing Price Updated: 7:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gsk Plc ADR

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
35 36 Next >
Do I Need to Get A Polio Vaccine? New York Sewer Discovery Triggers Fears About Paralysis-Inducing Virus
New York officials have detected polio in the city's wastewater, suggesting the virus has been circulating in the local area. 
Via Benzinga
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in GSK plc with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Recalled Heartburn Pill Zantac Sets Fire To Glaxo and Sanofi Shares As Billions In Market Value Goes Up In Smoke
Sanofi SA (NASDAQ: SNY), GSK Plc (NYSE: GSK), and Haleon Plc (NYSE: HLN) have lost a combined $40 billion in mar 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 22 companies reached new 52-week lows. 
Via Benzinga
GSK Confirms Rotavirus Vaccine Shortage, Hits Four African Countries: Report
Via Benzinga
Vir Biotech Shuns FDA Submission Plans For GSK-Partnered COVID-19 Treatment
Via Benzinga
GSK, PFE, SNY Stocks Fall on Zantac Litigation
You may think safety concerns about Zantac from 2019 are old news now, but GSK stock traders and others are worried about the repercussions. 
Via InvestorPlace
Pharma Stocks GSK, Sanofi And Haleon Lose Billions As Zantac Trial Looms
These companies are at the center of lawsuits claiming Zantac causes cancer. 
Via Investor's Business Daily
Sonos, Bumble And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  During Wednesday, 52 stocks hit new 52-week lows. 
Via Benzinga
Mersana, GSK Ink $1.36B Biobuck Deal For Cancer-Focused Therapy
Via Benzinga
Drug Behemoth GSK Delivers Strong Beat And Raise, But Shares Fell
The company expects full-year sales to grow 6%-8% and for earnings to rise 1%. 
Via Investor's Business Daily
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Dividend Income Update July 2022
The start of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. Let’s take a look back at... 
Via Talk Markets
New GSK Q2 Highlights: Shingles Vaccine Back In Demand, Antibiotics Recover, Forecast Boost
Via Benzinga
ADDING MULTIMEDIA GSK and IQVIA launch Vaccine Track, a data trend platform to help improve adult vaccination in communities nationwide
From GSK plc
Via Business Wire
Biotech Investors: August's Key PDUFA Catalysts You Must Know
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the... 
Via Benzinga
Recap Of Friday's Biotech Catalysts - End of The Day Summary
Via Benzinga
Stock Market Rally Powers Higher On Fed Rate Hints; Apple, Microsoft, Meta, Amazon, Google Key Earnings: Weekly Review
The major indexes made big moves amid key earnings and another big Fed rate hike. 
Via Investor's Business Daily
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap of Wednesday's Biotech Catalysts - End of The Day Summary
Via Benzinga
GSK Announces US FDA Approval of Benlysta (Belimumab) for Pediatric Patients With Active Lupus Nephritis
From GSK plc
Via Business Wire
IDEAYA's Cancer Candidate Shows Early Tumor Modulation
Via Benzinga
The 3 Best Market Sectors for the Second Half of 2022
Compelling themes will drive a recovery in some sectors over the second half of 2022. The following are the best market sectors to buy into. 
Via InvestorPlace
Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Jim Cramer Says This Stock Costs About $3, But 'If You Wait Long Enough' You Can Buy It For $2
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Blackstone Inc. (NYSE: BX) over Apollo Global Management Inc (NYSE: APO). 
Via Benzinga
Benzinga Before The Bell: Twitter Shareholder Proposal Date Set, T-Mobile's Strong FY22 Outlook, Shopify's Job Cuts And Other Top Financial Stories Wednesday, July 27
Reuters Monkeypox Emergency Could Last Months, According To Experts 
Via Benzinga
7 Dividend Stocks to Buy on the Dip
The stock market is volatile and bottoming, making it a good time to buy dividend stocks on the dip. Here are seven worth your consideration. 
Via InvestorPlace
This Analyst Says GSK Spin-Off Haleon Offers "Best Of Both Consumer Worlds"
Citi group has initiated coverage on GSK plc's (NYSE: GSK) consumer healthcare spin-off Haleon Plc (NYSE: HLN) with a Buy rating and a price target of 360p. 
Via Benzinga
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
35 36 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.